MX340859B - Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il )etil)-2-metilfenil)metanol. - Google Patents

Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il )etil)-2-metilfenil)metanol.

Info

Publication number
MX340859B
MX340859B MX2013005439A MX2013005439A MX340859B MX 340859 B MX340859 B MX 340859B MX 2013005439 A MX2013005439 A MX 2013005439A MX 2013005439 A MX2013005439 A MX 2013005439A MX 340859 B MX340859 B MX 340859B
Authority
MX
Mexico
Prior art keywords
imidazol
methylphenyl
methanol
pharmaceutical compositions
hyl
Prior art date
Application number
MX2013005439A
Other languages
English (en)
Other versions
MX2013005439A (es
Inventor
W Gil Daniel
E Donello John
I Dibas Mohammed
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2013005439A publication Critical patent/MX2013005439A/es
Publication of MX340859B publication Critical patent/MX340859B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con un método para disminuir la presión intraocular en un paciente en necesidad de tal tratamiento, el cual comprende administrar una cantidad terapéuticamente efectiva de una composición que comprende [3-(1-(1H-imidazol-4-il)etil)-2-metilfenil] metanol o sus enantiómeros o sus tautómeros, composiciones farmacéuticas que lo contienen y su uso como farmacéuticos.
MX2013005439A 2010-11-16 2011-11-10 Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il )etil)-2-metilfenil)metanol. MX340859B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41418010P 2010-11-16 2010-11-16
PCT/US2011/060236 WO2012067941A1 (en) 2010-11-16 2011-11-10 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Publications (2)

Publication Number Publication Date
MX2013005439A MX2013005439A (es) 2013-08-27
MX340859B true MX340859B (es) 2016-07-28

Family

ID=44999965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005439A MX340859B (es) 2010-11-16 2011-11-10 Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il )etil)-2-metilfenil)metanol.

Country Status (17)

Country Link
US (5) US20120149747A1 (es)
EP (3) EP2640382B1 (es)
JP (1) JP2013542991A (es)
KR (7) KR20200085936A (es)
CN (1) CN103298467A (es)
AR (1) AR083893A1 (es)
AU (1) AU2011329209B8 (es)
BR (1) BR112013012112A2 (es)
CA (2) CA3067290A1 (es)
DK (1) DK3093017T3 (es)
ES (1) ES2865118T3 (es)
IL (1) IL226384A (es)
MX (1) MX340859B (es)
RU (1) RU2013124526A (es)
SG (3) SG190322A1 (es)
TW (1) TW201304774A (es)
WO (1) WO2012067941A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566703B1 (en) 2009-02-13 2021-04-07 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504667A (en) * 1997-12-04 2003-03-28 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
CN1878569A (zh) * 2003-09-12 2006-12-13 阿勒根公司 用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2481412B1 (en) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
GB0715790D0 (en) 2007-08-13 2007-09-26 Summit Corp Plc Drug combination for the treatment of sialorrhoea
EP2320911B1 (en) * 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
EP3566703B1 (en) * 2009-02-13 2021-04-07 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Also Published As

Publication number Publication date
SG190322A1 (en) 2013-06-28
MX2013005439A (es) 2013-08-27
EP3093017A1 (en) 2016-11-16
US20200206193A1 (en) 2020-07-02
SG10201509423XA (en) 2015-12-30
KR20210080591A (ko) 2021-06-30
DK3093017T3 (da) 2021-04-06
KR20180096812A (ko) 2018-08-29
AR083893A1 (es) 2013-03-27
IL226384A0 (en) 2013-07-31
KR20140008316A (ko) 2014-01-21
AU2011329209A8 (en) 2017-03-09
EP2640382A1 (en) 2013-09-25
KR20200030626A (ko) 2020-03-20
KR20220158876A (ko) 2022-12-01
US20170172983A1 (en) 2017-06-22
US20220008393A1 (en) 2022-01-13
EP3795154A1 (en) 2021-03-24
CA2818144C (en) 2020-09-22
US20120149747A1 (en) 2012-06-14
IL226384A (en) 2017-06-29
KR101891846B1 (ko) 2018-08-24
RU2013124526A (ru) 2014-12-27
EP2640382B1 (en) 2016-10-19
WO2012067941A1 (en) 2012-05-24
JP2013542991A (ja) 2013-11-28
KR102090441B1 (ko) 2020-03-18
AU2011329209B2 (en) 2017-02-23
US20160067222A1 (en) 2016-03-10
CA3067290A1 (en) 2012-05-24
SG10201910521YA (en) 2020-01-30
CA2818144A1 (en) 2012-05-24
BR112013012112A2 (pt) 2016-09-27
AU2011329209B8 (en) 2017-03-09
TW201304774A (zh) 2013-02-01
ES2865118T3 (es) 2021-10-15
EP3093017B1 (en) 2021-01-06
AU2011329209A1 (en) 2013-06-13
KR102050187B1 (ko) 2019-11-28
KR102134117B1 (ko) 2020-07-15
CN103298467A (zh) 2013-09-11
KR20190133071A (ko) 2019-11-29
KR20200085936A (ko) 2020-07-15

Similar Documents

Publication Publication Date Title
MY191369A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl) -2-methylphenyl] methanol for lowering intraocular pressure
WO2010007116A3 (en) Pyridons as pdk1 inhibitors
GEP20146125B (en) Aminopyrimidines as syk inhibitors
WO2009106980A3 (en) Indazole derivatives
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2010014234A (es) Compuestos pirazol 436.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
MX2011012122A (es) Derivados de tiofeno.
WO2011056985A3 (en) Substituted heterocyclic compounds
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
IN2012DN03182A (es)
MX2010009462A (es) Derivados de indazol.
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2011091225A3 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
MX340859B (es) Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il )etil)-2-metilfenil)metanol.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments

Legal Events

Date Code Title Description
FG Grant or registration